Volume 20, Number 3—March 2014
Research
Hendra Virus Vaccine, a One Health Approach to Protecting Horse, Human, and Environmental Health
Deborah Middleton1
, Jackie Pallister1, Reuben Klein, Yan-Ru Feng, Jessica Haining, Rachel Arkinstall, Leah Frazer, Jin-An Huang, Nigel Edwards, Mark Wareing, Martin Elhay, Zia Hashmi, John Bingham, Manabu Yamada, Dayna Johnson, John White, Adam Foord, Hans G. Heine, Glenn A. Marsh, Christopher C. Broder, and Lin-Fa Wang
, Jackie Pallister1, Reuben Klein, Yan-Ru Feng, Jessica Haining, Rachel Arkinstall, Leah Frazer, Jin-An Huang, Nigel Edwards, Mark Wareing, Martin Elhay, Zia Hashmi, John Bingham, Manabu Yamada, Dayna Johnson, John White, Adam Foord, Hans G. Heine, Glenn A. Marsh, Christopher C. Broder, and Lin-Fa Wang
Table 3
Summary of sample analysis data from 10 horses in the 4 efficacy trials*
| Trial no, horse ID | Prechallenge antibody titer | Euthanized, dpc | Genome detection, sample, no. dpc |
Viral infectivity control |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PM tissue | Oral swab | Rectal swab | Nasal swab | Urine | Feces | Blood | Specimen | No. died/no. total | |||||
| 1 | Horse | 1/1 | |||||||||||
| V1 | 512, 1,024 | 8 | − | − | − | − | − | − | − | ||||
| V2 |
512, 1,024 |
9 |
− |
− |
− |
− |
− |
− |
− |
||||
| 2 | Guinea pig | 1/4 | |||||||||||
| V3 | 2,048, 4,096 | 7 | − | − | − | − | − | − | − | ||||
| V4 | 128, 256 | 8 | − | − | − | − | − | − | − | ||||
| V5 |
>4,096, >4,096 |
9 |
− |
− |
− |
− |
− |
− |
− |
||||
| 3 | Ferret | 2/2 | |||||||||||
| V6 | >4,096, >4,096 | 7 | − | − | − | − | − | − | − | ||||
| V7 |
>4,096, >4,096 |
8 |
− |
− |
− |
− |
− |
− |
− |
||||
| 4 | Ferret | 2/2 | |||||||||||
| V8 | 32, 32 | 7 | − | − | − | − | − | − | − | ||||
| V9 | 16, 32 | 8 | − | − | − | 2–4, 7 | − | − | − | ||||
| V10 |
16, 32 |
9 |
− |
− |
− |
− |
− |
− |
− |
||||
| *A 100-μg dose of Hendra virus soluble G glycoprotein was used in trials 1, 3, and 4; a 50-μg dose was used in trial 2. Genome was detected by PCR. ID, identification; dpc, days after challenge; PM, postmortem. − indicates a negative result. | |||||||||||||
1These authors contributed equally to this article.
Page created: February 19, 2014
Page updated: February 19, 2014
Page reviewed: February 19, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.